Get the Stockscreener App
1.08
8.47%
-0.10
After Hours:
1.06
-0.02
-1.85%
Atossa Therapeutics Inc stock is traded at $1.08, with a volume of 2.40M.
It is down -8.47% in the last 24 hours and up +35.27% over the past month.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
See More
Previous Close:
$1.18
Open:
$1.17
24h Volume:
2.40M
Relative Volume:
2.41
Market Cap:
$139.51M
Revenue:
-
Net Income/Loss:
$-26.91M
P/E Ratio:
-4.9091
EPS:
-0.22
Net Cash Flow:
$-19.57M
1W Performance:
+6.93%
1M Performance:
+35.27%
6M Performance:
+83.14%
1Y Performance:
-22.30%
1-Day Range:
$1.05
$1.20
1-Week Range:
$0.9702
$1.29
52-Week Range:
$0.5526
$1.66
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
10202 5TH AVENUE NE, SEATTLE, WA
Compare ATOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
1.08 | 152.42M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
Regression analysis insights on Atossa Therapeutics Inc. performancePortfolio Gains Summary & High Accuracy Trade Signal Alerts - newser.com
What MACD and RSI say about Atossa Therapeutics Inc.July 2025 Institutional & High Conviction Buy Zone Picks - newser.com
Can Atossa Therapeutics Inc. (YAG2) stock stage a strong rebound this quarterWeekly Investment Recap & Weekly Watchlist of Top Performers - newser.com
Can a trend reversal in Atossa Therapeutics Inc. lead to recoveryEarnings Growth Report & Stepwise Swing Trade Plans - newser.com
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Pueblo Chieftain
Is Atossa Therapeutics Inc. stock ready for a breakoutJuly 2025 Sector Moves & Breakout Confirmation Alerts - newser.com
How to forecast Atossa Therapeutics Inc. trends using time seriesGap Down & Weekly Market Pulse Updates - newser.com
Is Atossa Therapeutics Inc. stock entering bullish territoryMarket Growth Report & Fast Moving Stock Trade Plans - newser.com
Comparing Atossa Therapeutics Inc. in custom built stock radars2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - newser.com
Published on: 2025-10-10 02:05:17 - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Atossa Genetics (NASDAQ:ATOS) - MarketBeat
Can Atossa Therapeutics Inc. (YAG2) stock deliver double digit returnsOptions Play & Weekly Breakout Watchlists - newser.com
Signal strength of Atossa Therapeutics Inc. stock in tech scannersTrade Entry Report & Weekly Momentum Picks - newser.com
Can Atossa Therapeutics Inc. (YAG2) stock reach $200 price targetQuarterly Trade Report & Low Volatility Stock Recommendations - newser.com
Atossa Therapeutics (ATOS) Announces Upcoming Virtual Meeting - GuruFocus
Atossa streamlines breast cancer trial to focus on 2026 NDA plans - Investing.com
Atossa Therapeutics streamlines Evangeline breast cancer clinical trial to prioritize for 2026 NDA-enabling activities - MarketScreener
40–65-Patient EVANGELINE Redesign: Atossa Prioritizes 2026 NDA‑Enabling Activities, Reduces Study Costs - Stock Titan
Atossa Therapeutics Inc. stock retracement – recovery analysisEarnings Growth Report & Free Fast Gain Swing Trade Alerts - newser.com
Can Atossa Therapeutics Inc. stock hit analyst price targetsWeekly Risk Report & Consistent Income Trade Recommendations - newser.com
Atossa Therapeutics appoints Janet Rea as SVP of R&D By Investing.com - Investing.com Nigeria
Atossa Therapeutics appoints Janet Rea as SVP of R&D - Investing.com
What drives Atossa Therapeutics Inc YAG2 stock priceDouble Top/Bottom Patterns & Superior Trading Ideas - earlytimes.in
Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones - StreetInsider
Veteran Drug Approval Expert Returns to Atossa Therapeutics to Advance Breakthrough Breast Cancer Treatment - Stock Titan
Goldman Sachs Group Inc. Lowers Holdings in Atossa Genetics Inc. $ATOS - Defense World
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Daily Jeffersonian
What analysts say about Atossa Therapeutics Inc stockSector-Based Investing & Build Capital Safely - earlytimes.in
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atossa Therapeutics Inc Stock (ATOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Remmel H. Lawrence | Director |
Mar 26 '25 |
Buy |
0.70 |
10,000 |
7,000 |
10,257 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):